Offering high-quality voice, data, and marketing solutions that help businesses focus on their core operations, Crexendo, Inc. (OTCQX: CXDO) is a competitive local exchange carrier (CLEC) cloud services company that offers award-winning cloud telecommunications, broadband Internet, and other cloud business services. The company provides critical voice and data technology infrastructure for startups, small and medium-sized business (SMB), and small enterprise markets, offering enterprise-caliber cloud services at affordable monthly rates. The company’s world-class services help businesses significantly increase their productivity, and Crexendo is payment card industry-compliant and CLEC-licensed for its cloud web, telecommunications, and network services.

Guided by a team of industry leaders, Crexendo is dedicated to maintaining secure and reliable cloud systems. Beginning with a cutting-edge data center that has multiple redundancy levels and the very best security defenses, Crexendo epitomizes the very highest standards of security and reliability.

Crexendo’s cloud-based phone systems transcend standard phone systems, providing businesses with advanced calling features that cost significantly less. Businesses get the features they need and a full array of productive telecommunication tools, but in the cloud and at a lower price point.

Through Crexendo Mobile, businesses are able to revolutionize their productivity with a simple download. Crexendo Mobile enables businesspeople to access all the features of their office phone right on their existing mobile device, which lets them seamlessly continue their business communications from office to home and everywhere in-between. Crexendo Mobile can also be downloaded to other wireless devices, including tablets. Crexendo Mobile lets individuals make and take calls using their office phone number, showing that office number as their caller ID. This innovative solution additionally separates business voicemails from personal messages and lets users listen to business-related voice messages in any order via visual voicemail. Users can view call times, call dates, and make return phone calls using Crexendo call logs, and calls can be made via 3G/4G networks so that monthly cell phone minutes aren’t impacted. What’s more, Crexendo lets businesspeople traveling internationally call the United States for free using CrexMo.

Crexendo’s cutting-edge solutions give businesses unparalleled freedom, cutting the cord between the office and the outside world and improving productivity like never before.

For more information, visit the company’s website at www.Crexendo.com

Algae Dynamics Corp (OTCQB: ADYNF) is focused on developing proprietary research and products involving botanical oils derived from cannabis and algae.

The original core of the company’s product development strategy was the extraction of Omega-3 fatty acids from certain strains of algae with high concentrations of DHA to create various nutraceutical products. As a result of the many demonstrated health benefits of other botanical oils, most notably cannabis oil, Algae Dynamics developed a strategy aimed at developing products that combined the health benefits of algae and cannabis oils. Capitalizing on the burgeoning demand for cannabis oil and other smoke-free alternatives to marijuana consumption will help support ongoing initiatives to create and market research-driven product formulations.

Although the company is publicly traded in the U.S., business is conducted in Canada with no exposure to U.S. federal regulation involving cannabis. The Canadian cannabis oil extraction marketplace is projected to grow from C$1 million in 2015 to C$1.7 billion in 2020, which is more than a 1,000-fold increase. With the Government of Canada indicating a target date for full legalization on or before July 2018, numerous opportunities for sales in extracts and oils will open up very soon.

Using Colorado as a comparable example, a study performed by Mackie Research Capital found that 45% of dried marijuana users in the state would eventually convert to marijuana extracts and oils. This is because most consumers taking cannabis for medical purposes are increasingly looking for delivery systems that do not involve smoking marijuana. The market’s attractiveness can be further realized when considering that the Canada’s licensed producer marketplace is far less competitive with 45 current licensed producers for the whole country vs. 624 licensed cultivators in Colorado.

Collaborating with prominent Canadian universities is a core part of the Algae Dynamics’ plan to bolster cannabis extraction expertise, develop premium products and add to its portfolio of intellectual property. Through its agreements with the University of Waterloo and the University of Western Ontario, the company is focusing primarily on the use of extracts from cannabis oil and algae oil in the context of cancer as well as the development of new pharmacotherapies for mental health.

Near-term goals include expanding research and development work with existing and new Canadian universities, securing supply/service agreements with licensed producers, and submitting an application to Health Canada to become a licensed producer of medical marijuana and ultimately have a license to sell products derived from cannabinoids. Algae Dynamics also owns a proprietary technology for the cultivation of low cost, highly pure algae biomass, which will be developed as a vertical integration strategy in the future to support the need to source algae oil for research-driven product formulations. The management team leading these initiatives has nearly a century of beneficial experience spanning from management and process experience to successful fund raising and commercialization.

As part of its key objective to be the #1 research Canadian cannabis oil research-driven product formulator, the company has also formed a strong team of scientific and strategic advisors that complement ongoing R&D relationships and initiatives. Individuals who support the company’s initiatives include Dr. Jonathan Blay PhD, FRSB, FIBMS, Csci, CBiol, who performs research and product development on cannabis oil and its constituents in the context of colorectum, pancreas, breast and prostate cancers; and Dr. Steven Laviolette, BSc, PhD, who performs research and product development on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety and schizophrenia.

With such a strong foundation laid in the areas being pursued, Algae Dynamics is well positioned to execute on its carefully developed business plan to fast-track to revenue growth while having a longer-term strategy to build a sustainable enterprise-building opportunity in a rapidly expanding market.

For more information, visit the company’s website at www.AlgaeDynamics.com

Let us hear your thoughts: Algae Dynamics Corp. Message Board

Despite the fire-breathing from Attorney-General Jefferson Beauregard Sessions III, there is a distinct feeling that marijuana has entered the mainstream now that Goldman Sachs has initiated coverage on GW Pharma (NASDAQ: GWPH). GW Pharma is the biopharmaceutical that developed the cannabinoid-derived Sativex to treat spasticity due to multiple sclerosis (MS), now approved by regulatory authorities in 29 countries. The success of GW Pharma and other pharmaceutical companies focused on cannabinoid research has produced an exciting new field with a lot of promise, cannabis biotech, and InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is staking a position in that emerging market. The Vancouver, Canada-based outfit is a pre-clinical stage biopharmaceutical company that is currently testing cannabinoid derivatives to treat epidermolysis bullosa and glaucoma and a full pipeline of other drug candidates.

Cannabinoids are turning out to be big business. GW Pharma presently has a market cap of around $3.0 billion, yet Goldman Sachs, in that initial report, intimated the company might be worth more. It set a target price of $189 on the stock, currently trading at just above $116, which would value the company at close to $5 billion. GW Pharma is set to file a New Drug Application (NDA) with the FDA in the first half of 2017 for Epidiolex, the company’s cannabis-based treatment for rarer forms of epilepsy.

Axim Biotechnologies, Inc. (OTCQB: AXIM) is another player showing value. The company owns the patent for chewing gum as a delivery method for cannabinoids, which it has developed into two separate products. Its current market cap is about $500 million. Cara Therapeutics, Inc. (NASDAQ: CARA), meanwhile, is researching therapies that target the CB1 and CB2 cannabinoid (CB) receptors. Its most advanced CB compound, CR701, is in preclinical development. The company’s market value is about $556 million. Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) has a different focus. This biotech is studying synthetic cannabinoid therapeutics across multiple therapeutic areas. It has a market cap of over $220 million.

Research into the properties of cannabis was galvanized after Raphael Mechoulam and Yehiel Gaoni first isolated delta-9-tetrahydrocannabinol (THC) in 1963. Then, cannabinoid research became an even more exciting area of scholarship in 1992 when the first endocannabinoid, anandamide, was discovered. An endocannabinoid is a cannabinoid that is manufactured by the body. The fact that our bodies were producing the very same substances found in cannabis raised some very interesting questions.

Now we know that residing within most life forms (basically everything on our planet with the exception of insects) there is an extensive molecular signaling network known as the endocannabinoid system, which controls many functions. It has been said that ‘the endocannabinoid system is possibly the single-most important system within our entire bodies – responsible for maintaining homeostasis’ (http://dtn.fm/8Q5dt). Consequently, the aim of much cannabinoid research has been to provide cannabinoids to the body when, for one reason or another, the body fails to provide adequate quantities.

Presently, InMed Pharmaceuticals has two promising drug candidates undergoing pre-clinical trials. The first, INM-750, is for the treatment of a rare genetic connective tissue disorder called epidermolysis bullosa (EB), which affects roughly one out of every 20,000 births in the United States. There is an estimated patient population of about 25,000 with this condition in the U.S. alone. Globally, the market potential is about $1.0 billion.

The second drug, INM-085, treats glaucoma, a leading cause of blindness. INM-085 works by reducing the elevated intra-ocular pressure that is often associated with glaucoma. The National Institutes of Health estimates that more than three million Americans currently have glaucoma, and that the disease has blinded more than 120,000. INM-085 has a global market potential of close to $6.0 billion. Cannabinoid research is proving to be a truly exciting field.

For more information, visit the company’s website at www.InMedPharma.com

Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board

Net Element, Inc. (NASDAQ: NETE) is seen reaching revenues of $75 million in 2018 by a Zacks Research Report issued in May 2017 (http://nnw.fm/wV8IN). In the Zacks Small-Cap Research Report, it is estimated that the company’s sales will reach $63 million in 2017 and $74.6 million in 2018. Net Element reported actual revenues of $54.3 million in 2016.

Net Element is a high technology financial group that digitally processes transactions in an omni-channel environment in what is becoming a world of cashless transactions. It processes the electronic transactions from both point-of-sale and mobile devices.

Driving this forecast revenue growth is a continuation of the increases from Net Element’s North American Transaction Group. It is seen by Zacks as delivering 41% and 20% year-over-year growth in 2017 and 2018, respectively, for a total of $64.2 million in sales in 2018. By far, it remains as the single biggest contributor of the three components in the Net Element company. The other two are mobile payments and PayOnline.

Zacks has an investment thesis that incorporates the belief that New Element is a growth company in the payments industry that should benefit from mobile and online payments from the U.S., Russia and the Middle East. Eventually, Zacks’ research said, these payments are expected to achieve a global reach. The other thesis by the research company is that Net Element’s Aptito line provides differentiation and value-added services to its generic card processing business.

By sacrificing short-term profits and placing its focus on long-term growth, the company is creating a “long tail, future profitability and higher margins,” the report said. “As long as public markets are willing to fund the company through equity, this strategy may play out in future years.”

Zacks added that NETE’s PayOnline is being certified in the U.S. in the near-term future. The company’s Unified Payments would then be able to implement the platform. By not using third party payments at that time, NETE could then save costs and increase its margins. Net Element believes that as many as 15% of its Unified Payments transactions would be impacted positively, per the report.

For more information, refer to www.NetElement.com

Moxian, Inc. (NASDAQ: MOXC) offers investors a high risk-high reward opportunity in China’s online-to-offline (O2O) marketplace, and the key is the high gross margin percentages of the company’s revenues, according to the SeeThruEquity (http://nnw.fm/dee5W) research report on the company. Shenzhen, China-based Moxian has a gross margin of 77.4% — second-highest of all of its significantly higher market cap competitors, the report says.

MOXC is a development stage company that’s currently executing its marketing strategy of converting its two O2O platforms from unpaid to paid. Moxian+ is a business platform which is already serving, at no charge, some 30,000 small market enterprises (SMEs). Its other app is Moxian User, a consumer app which already has some 300,000 users. The marketing effort is to convert the free users on both apps to paid, then gain more revenues from paid subscriptions, mobile advertising, transaction and licensing fees and OEM and distribution fees.

SeeThruEquity notes that MOXC believes it can achieve a revenue total of $25 million in 2018. The company anticipates revenue of $11 million in 2017. Key to achieving its profit goals is MOXC’s high profit margins from its own sales and mobile advertising, as the company believes it would realize lower margins from third party transactions.

Within the O2O market, MOXC may face formidable competitors which are significantly larger in terms of market cap, but MOXC boosts high profit margins. As previously indicated, its 77.4% gross margin percentage is the second-highest in a field that includes seven other firms. SeeThruEquity believes that Moxian will invest in technology, sales and marketing to differentiate its products in this market. It is seen as also leveraging the existing customer base of its merchant partners.

For more information, visit www.Moxian.com

InMed Pharmaceuticals, Inc. (OTCQB: IMLFF), a pre-clinical stage biopharmaceutical company that specializes in the development of therapies through research and development into the pharmacology of cannabinoids and drug delivery systems, continues to get positive media coverage of ongoing operational developments, propelled by the company’s impressive leadership team.

Insider Financial highlighted InMed Pharmaceuticals as a “Cannabis Runner” in an article back in January, stating that “This is the kind of company that needs to maintain a positive news flow in order to keep investors interested.” More recently, Forbes released an article describing the company as “more than just another cannabis drug company”. This was due to the excitement surrounding the development of its proprietary cannabinoid manufacturing system and sought-after database, its biosynthesis for cannabinoids that is similar to that used to create synthetic insulin, as well as its ability to leverage some of the leading experts in the pharmaceutical industry.

Although the company’s pipeline is expected to generate a significant amount of attention in 2018, InMed Pharmaceuticals’ manufacturing system and database are catching the eye of investors and biotech companies. THC and CBD have, of course, been used for treating medical conditions, but there are now more than 90 different cannabinoids identified in one plant, and all of these are thought to serve various purposes. InMed has managed to plug these different cannabinoids into its system, allowing the bioinformatics compounds to test them against various illnesses and drug compounds, matching the right cannabinoids to help fight specific diseases.

This tool has helped the company identify two therapies, one for epidermolysis bullosa (EB), a rare skin disease found in children, and one for glaucoma, a degenerative condition that causes damage to a person’s optic nerve. In addition to all of the above, the company has now developed a method of biosynthesis similar to that used to create synthetic insulin, but for cannabinoids. This process is not only cheaper, but quicker, and it gives access to cannabinoids that are not currently profitable to turn into drugs.

These are all developments that owe their success to leadership that comprises some of the world’s most experienced professionals in the pharmaceutical, drug discovery, cannabinoid therapy, and R&D industries (http://dtn.fm/DTx95).

For more information, visit the company’s website at www.InMedPharma.com

Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board

With demand constantly on the rise and the recent closing of several mining operations in China, the global shortage of zinc has grown exponentially. The zinc shortage is expected to widen to 360,000 tons this year (http://dtn.fm/qab6X), according to market analysts, but the figure might grow further in wake of China’s decision to completely halt production as part of a nationwide environmental crackdown on the local steel industry. Major zinc exploration projects such as Canadian mining company Kootenay Zinc Corp.’s (CSE: ZNK) (OTCQB: KTNNF) Sully property could have a major impact on the global output of zinc and significantly narrow the offer-demand gap.

Responsible for roughly 50 percent of the global zinc output, China has been relying heavily on imports in recent months, further putting strain on the dwindling supply of the metal. China is both the largest consumer and producer of zinc, accounting for roughly five million tons of output before the crackdown. Zinc prices have also been more volatile in recent months, after reaching an all-time high of $3,000 a ton in February of this year and now settling to approximately $2,400-$2,500, as initially forecast by experts last year.

Despite the price drop, zinc remains one of the most attractive investment opportunities on the metals market, with mining companies rushing to expand current reserves or discover new ones in view of helping solve the global shortage problem. Additionally, any mining company that will release large volumes of zinc on the market could certainly make a sizeable profit and see its stock value soar.

Vancouver-based zinc mining and development corporation Kootenay Zinc Corp. is set to capitalize on the current market situation when it fully begins extraction operations at its massive Sully Project. Located just 30 miles (18 kilometers) from the legendary Sullivan Mine, the Sully Project seems to meet all the conditions for a highly successful zinc extraction operation, with all tests so far indicating the presence of a large deposit. Sully shares several geological features with the Sullivan Mine, which was one of the world’s largest deposits of silver, lead and zinc. Some of these features include: being in the same sedimentary basin, having the exact stratigraphic time horizon, gravity anomaly indicating excess mass at Sully comparable to Sullivan, Pb-Zn present in drill core, outcrop and soil geochemical anomaly.

Kootenay Zinc Corp. has not issued any estimate as to how much zinc it expects to extract at Sully, but all signs point to the presence of a massive SEDEX deposit in the area. The project is being managed by Paul Ransom, a reputed geologist and Sullivan SEDEX deposit expert who has worked with several other mega-deposits throughout his career. It should be noted that the nearby Sullivan Mine, which was in operation for roughly 100 years, produced 17 million tonnes of zinc and lead and 337 million ounces of silver prior to its closing in 2001. The estimated value of Sullivan’s total output, calculated at current price values, was roughly $49 billion.

To find out more about Kootenay Zinc Corp. and the company’s exploration efforts at Sully, visit www.KootenayZinc.com

Let us hear your thoughts: Kootenay Zinc Corp. Message Board

Nowhere seems safe anymore in a world filled with evildoers, the mentally deranged, radical religious extremists, or anyone with criminal intent. One of the latest acts of heinous depredation killed 22 and injured 166 in a suicide bombing at Manchester Arena — kids, mostly young girls, out for a night of revelry at an Ariana Grande concert. Lives destroyed and dreams demolished in split seconds of stark terror. Civilized society and grieving families worldwide beg for answers and protection from the insanity.

Public places, venues and events are nearly impossible to secure. So called soft targets have become targets of choice. By nature, they’re much harder to monitor and screen — thus easier to attack. Wherever crowds of people gather, stand in line or collectively commute, they become attractive targets. It isn’t the size of the bomb that matters most, it’s where it’s detonated.

Conventional screening systems just identify the presence of metal objects, not what those objects may be. It could be a belt buckle, keys or phone, and monitoring subways, schools and stadiums becomes nearly impossible. Current screening systems are inadequate, since they just don’t offer precise enough information to be effective and require compliance on the part of the target subject.

Patriot One Technologies, Inc. (TSX.V: PAT) (OTCQB: PTOTF) has a solution. Patriot One has an exclusively licensed system to detect concealed weapons utilizing novel radar technologies. This first of its kind concealed weapons detection system is designed to detect weapons being carried on people in public places using radar technology called PATSCAN CMR™, which Patriot One has licensed from McMaster University.

Patriot One’s patent-pending system enables stand-off detection, even on moving targets, with the ability to learn, analyze and identify new threats upon deployment. The system actually gets better and smarter at detecting hidden weapons with each screening instance. The technology is able identify passersby carrying a knife, gun or bomb by analyzing metal content and relating it to a database of known weapon signatures.

Patriot One’s PATSCAN CMR™ system is small enough for unobtrusive door, hall or entryway installation with no privacy concerns since no target images are generated. The system doesn’t require line-of-sight, works on moving crowds and is the first cost-effective solution for active shooter prevention on the market. Early warning is the key to effective deployment of timely countermeasures, and widespread use of Patriot One’s pioneering detection technology could be the sought-after deterrent desperately needed to reduce the horrors inflicted on far too many around the world today.

For more information, visit the company’s website at www.Patriot1Tech.com

Let us hear your thoughts: Patriot One Technologies, Inc. Message Board

The status quo never likes change, nor the upstarts that attempt to initiate innovation. When innovation and change occur, the entrenched typically lose prominence, certainly preeminence, and often times money. Disagreement and conflict ensue, but the strongest survive and seem to stay in power. It happens across the full spectrum of businesses, and it’s happening again now with Nasdaq, Inc. and Bats Global Markets.

Most are familiar with Nasdaq, the world’s first electronic stock market. It was founded in 1971 by the National Association of Securities Dealers, the financial self-regulatory agency of its era. At first, Nasdaq was only a quotation system, but, eventually, it effectuated the majority of trades that previously had been executed through the over-the-counter system where trades between parties occurred without exchange supervision. Over time, Nasdaq helped lower the bid-ask spread in stocks and became more of a true stock exchange by adding trade and volume reporting and automated trading systems. It was the first stock exchange to start online trading and touted itself as “the stock market for the next hundred years“. A hundred year superiority was not in the cards, but Nasdaq did attract new growth companies such as Microsoft, Oracle, Apple, and Cisco, and it helped modernize the IPO process. In 1992, Nasdaq merged with the London Stock Exchange and formed the first globally linked markets. In 2000, it was spun off and went public as an independent exchange and was licensed as a national securities exchange in 2006, about the time its claim of a one-hundred year reign was being challenged.

Bats Global Markets was founded in June 2005 by a computer programmer, Dave Cummings, after watching the consolidation and monopolization of the exchanges by the NYSE and Nasdaq. Cummings publicized the Bats service by sending solicitation emails to companies highlighting the benefits of trading on platforms other than the NYSE or Nasdaq, which had eliminated competition and raised prices for their services. The Bats system charged less, which helped attract other brokerage firms and hedge funds to engage with the upstart trading system. In 2008, Bats entered the European equities markets to compete against global incumbent securities exchanges. Bats tried to go public in 2012 but withdrew due to a calamitous trading system glitch and admitted what it called a system issue. In March of 2017, Bats was acquired by CBOE Holdings, the owner of the Chicago Board Options Exchange, for $3.2 billion. Established in 1973, the CBOE is the largest options exchange in the U.S., and the acquisition of Bats put the CBOE in direct competition with Nasdaq and the NYSE.

The latest contest between these trading behemoths centers on Bats wanting to offer brokers a type of order that would give them the same closing prices derived from the closing auctions on Nasdaq and the New York Stock Exchange for stocks listed on those exchanges, but with lower execution fees. Nasdaq said in a letter to the U.S. Securities and Exchange Commission that such a move by Bats, which currently only lists ETFs and the stock of its parent company, CBOE Holdings, would fragment the market close and result in less accurate pricing. NYSE has also blasted the Bats proposal, saying that diverting trades away from closing auctions would add to volatility and distort prices. (http://www.reuters.com/article/us-nasdaq-bats-marketclose-idUSKBN1942GM?utm_source=applenews)

This is a turf war among giants and one can only believe that whoever wins and becomes dominant will adjust prices to their own benefit. Meet the new boss, same as the old boss.

A recent Forbes (http://dtn.fm/2WfWR) article shows just how far Additive Manufacturing (AM), a.k.a. 3D Printing, has come, reporting that the government of Dubai, United Arab Emirates, ‘has set a target for 25 percent of buildings to be 3D-printed by 2030.’ Apparently, the AM industry now believes it has the technology to “print” houses. That technological prowess also appears to extend to smaller objects, much smaller, where the challenges are different but just as formidable. An Economist feature (http://dtn.fm/71FDh) tells how a Chinese contract manufacturer is using 3D printers ‘to print electronic circuits, such as antennae and sensors, directly into products instead of making those components separately and assembling them into the devices.’ Printers need ink, however, and 3D printers need the special kind produced by PV Nano Cell (OTCQB: PVNNF). Under the Sicrys™ brand, the innovative Israeli outfit has developed a menu of customized single crystal nanometric conductive inks for use in the manufacture of a wide range of electronic devices.

The devices that PVNNF’s inks are designed to work with are less than Lilliputian. A nanometer is one-billionth of a meter or, put another way, it would take 25,400,000 nanometers in a line to cover a distance of just one inch. These tiny devices are, more often than not, required to transmit electrical signals and, consequently, need conductive inks of quality. Sicrys™ inks serve a wide range of applications that demand high-performance conductive inks, including mass produced printed electronics applications such as printed circuit boards, antennas, sensors, and touch screens, as well as photovoltaic applications, and are available in both silver-based and copper-based formulations.

PVNNF is bolstering its intellectual property (IP) war chest with a plethora of patents. In May 2017, the company announced (http://dtn.fm/xVPO4) that the Japanese Patent Office (JPO) had granted its silver nano particles patent. The company has already been granted patents in four countries for its silver single crystal nano particles based dispersions and inks and has submitted patents related to its silver and copper nano particles in nine other countries. To date, PVNNF has submitted patent applications for both its silver and copper nano particles in Brazil, China, Europe, India, Israel, Japan, Russia, South Korea, the United Kingdom and the U.S.

Owing to its general applicability, the Sicrys™ portfolio of conductive inks is appearing in many potentially lucrative market segments. For example, the market for “printing” antennas is about $0.5 billion, while for photovoltaic (PV) metallization it’s about $1.8 billion. For flexible and customized electronics, market size is estimated at around $2.0 billion, and for printed circuit boards (PCB) it is about $6.0 billion. The inks are already in use. Albuquerque, New Mexico-based Optomec prints antennas for the mobile industry using Sicrys™ inks, and Stratasys, a pioneer in developing 3D printing technologies, uses Sicrys™ too, as does inkjet technology provider Pixdro.

In the world of 3D printing, PV Nano Cell’s Sicrys™ ink family is hot off the press. The company continues its quest to develop the very best conductive inks for use in solar PV and printed electronics applications.

For more information, please visit www.PVNanoCell.com